SWIFT - SWIss Factor XIII Trial in PPH

PHASE4RecruitingINTERVENTIONAL
Enrollment

988

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions
Postpartum HemorrhageCoagulation DisorderCoagulation Factor DeficiencyHemorrhagePostpartum Complication
Interventions
DRUG

Fibrogammin

Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing

Trial Locations (9)

1005

RECRUITING

University Hospital Lausanne, Lausanne

1205

NOT_YET_RECRUITING

University Hospital Geneva, Geneva

3010

RECRUITING

Inselspital-University Hospital Bern, Bern

4031

RECRUITING

University Hospital Basel, Basel

5404

RECRUITING

Cantonal Hospital Baden, Baden

8091

RECRUITING

University Hospital of Zurich, Zurich

8125

RECRUITING

Spital Zollikerberg, Zollikerberg

8401

RECRUITING

Cantonal Hospital Winterthur, Winterthur

9007

RECRUITING

Cantonal Hospital St. Gallen, Sankt Gallen

All Listed Sponsors
collaborator

Swiss National Science Foundation, Switzerland

UNKNOWN

lead

Christian Haslinger

OTHER